Ionis Pharmaceuticals (IONS) Competitors $27.09 -1.43 (-5.01%) Closing price 04:00 PM EasternExtended Trading$26.80 -0.29 (-1.09%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IONS vs. UTHR, BMRN, INCY, NBIX, EXEL, EXAS, HALO, MDGL, RGEN, and ALKSShould you be buying Ionis Pharmaceuticals stock or one of its competitors? The main competitors of Ionis Pharmaceuticals include United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), Repligen (RGEN), and Alkermes (ALKS). These companies are all part of the "biotechnology" industry. Ionis Pharmaceuticals vs. United Therapeutics BioMarin Pharmaceutical Incyte Neurocrine Biosciences Exelixis Exact Sciences Halozyme Therapeutics Madrigal Pharmaceuticals Repligen Alkermes United Therapeutics (NASDAQ:UTHR) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, community ranking, valuation, institutional ownership and profitability. Do insiders & institutionals have more ownership in UTHR or IONS? 94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 11.9% of United Therapeutics shares are held by company insiders. Comparatively, 2.7% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has stronger valuation & earnings, UTHR or IONS? United Therapeutics has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUnited Therapeutics$2.88B4.56$984.80M$24.6011.89Ionis Pharmaceuticals$705.14M6.11-$366.29M-$3.04-8.91 Do analysts rate UTHR or IONS? United Therapeutics currently has a consensus target price of $388.25, indicating a potential upside of 32.75%. Ionis Pharmaceuticals has a consensus target price of $58.37, indicating a potential upside of 115.46%. Given Ionis Pharmaceuticals' higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than United Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score United Therapeutics 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.67Ionis Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.67 Is UTHR or IONS more profitable? United Therapeutics has a net margin of 40.31% compared to Ionis Pharmaceuticals' net margin of -64.25%. United Therapeutics' return on equity of 19.22% beat Ionis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets United Therapeutics40.31% 19.22% 16.15% Ionis Pharmaceuticals -64.25%-100.05%-15.70% Which has more risk and volatility, UTHR or IONS? United Therapeutics has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500. Does the MarketBeat Community believe in UTHR or IONS? Ionis Pharmaceuticals received 103 more outperform votes than United Therapeutics when rated by MarketBeat users. However, 62.58% of users gave United Therapeutics an outperform vote while only 60.19% of users gave Ionis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformUnited TherapeuticsOutperform Votes59762.58% Underperform Votes35737.42% Ionis PharmaceuticalsOutperform Votes70060.19% Underperform Votes46339.81% Does the media refer more to UTHR or IONS? In the previous week, United Therapeutics had 12 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 31 mentions for United Therapeutics and 19 mentions for Ionis Pharmaceuticals. United Therapeutics' average media sentiment score of 1.58 beat Ionis Pharmaceuticals' score of 0.71 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 28 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Ionis Pharmaceuticals 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryUnited Therapeutics beats Ionis Pharmaceuticals on 13 of the 18 factors compared between the two stocks. Remove Ads Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IONS vs. The Competition Export to ExcelMetricIonis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.31B$6.32B$5.24B$7.07BDividend YieldN/A2.85%4.87%4.05%P/E Ratio-8.916.7221.2017.47Price / Sales6.11186.91356.3585.24Price / CashN/A65.6738.1634.64Price / Book7.325.576.233.79Net Income-$366.29M$141.67M$3.20B$247.10M7 Day Performance-13.03%-11.44%-8.32%-7.32%1 Month Performance-17.78%-14.59%-3.36%-10.20%1 Year Performance-36.75%-18.30%2.72%-7.41% Ionis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IONSIonis Pharmaceuticals4.0777 of 5 stars$27.09-5.0%$58.37+115.5%-34.9%$4.31B$705.14M-8.91800Analyst ForecastGap DownUTHRUnited Therapeutics4.8587 of 5 stars$308.27+0.4%$388.25+25.9%+32.9%$13.85B$2.88B13.54980Positive NewsBMRNBioMarin Pharmaceutical4.8735 of 5 stars$70.69-1.0%$94.00+33.0%-22.2%$13.49B$2.85B32.133,401Analyst DowngradeNews CoveragePositive NewsINCYIncyte4.6061 of 5 stars$60.55-0.1%$74.88+23.7%+12.9%$11.72B$4.24B224.272,320Positive NewsNBIXNeurocrine Biosciences4.8331 of 5 stars$110.60-2.3%$165.38+49.5%-25.2%$11.03B$2.36B33.621,200Analyst ForecastNews CoveragePositive NewsGap DownEXELExelixis4.4246 of 5 stars$36.92+0.6%$37.59+1.8%+54.8%$10.33B$2.17B20.861,220Positive NewsGap DownEXASExact Sciences4.3532 of 5 stars$43.29-0.8%$70.26+62.3%-39.2%$8.04B$2.76B-7.776,400Positive NewsHALOHalozyme Therapeutics4.126 of 5 stars$63.810.0%$62.78-1.6%+53.9%$7.88B$1.02B18.60390Positive NewsMDGLMadrigal Pharmaceuticals3.3189 of 5 stars$331.23+1.0%$378.44+14.3%+33.4%$7.31B$180.13M-13.2190Positive NewsGap DownRGENRepligen4.6556 of 5 stars$127.24-4.6%$178.64+40.4%-31.4%$7.14B$634.44M-249.492,020Positive NewsGap DownALKSAlkermes4.762 of 5 stars$33.02-0.6%$39.38+19.3%+20.2%$5.37B$1.56B15.221,800Gap Down Remove Ads Related Companies and Tools Related Companies UTHR Competitors BMRN Competitors INCY Competitors NBIX Competitors EXEL Competitors EXAS Competitors HALO Competitors MDGL Competitors RGEN Competitors ALKS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IONS) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredWall St. Icon: Looming Financial Tsunami Could Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event could hit the America...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IONS Stock Free IONS Stock Alerts